Literature DB >> 20016875

Amelioration of hyperglycemia by intestinal overexpression of glucagon-like peptide-1 in mice.

Meng-Ju Liu1, Jaeseok Han, Young-Sun Lee, Mi-Sung Park, Seungjin Shin, Hee-Sook Jun.   

Abstract

To investigate whether the local production of glucagon-like peptide-1 (GLP-1) in the intestine can differentiate intestinal stem/progenitor cells into insulin-producing cells, we intra-intestinally injected a recombinant adenovirus expressing GLP-1 (rAd-GLP-1) into diabetic mice. There were no significant differences in body weight or food intake between rAd-GLP-1- and rAd-betaGAL-treated control mice. rAd-GLP-1-treated mice showed intestinal insulin mRNA expression, insulin- and glucagon-positive cells in the intestine, and significantly increased serum insulin, but not glucagon. rAd-GLP-1 injection significantly reduced blood glucose levels and improved glucose tolerance compared with controls. Expression of transcription factors related to beta cell differentiation, neurogenin 3 (ngn3) and neurogenin differentiation factor (NeuroD), was detected in the intestine at 2 weeks after rAd-GLP-1 injection. We suggest that expression of GLP-1 in the intestine by intra-intestinal delivery of rAd-GLP-1 may induce differentiation of intestinal stem/progenitor cells into insulin-producing cells, mediated by ngn3 and NeuroD expression, contributing to lowered blood glucose levels in diabetic mice.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20016875     DOI: 10.1007/s00109-009-0571-z

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  28 in total

Review 1.  Pancreatic organogenesis--developmental mechanisms and implications for therapy.

Authors:  Helena Edlund
Journal:  Nat Rev Genet       Date:  2002-07       Impact factor: 53.242

2.  PDX-1 induces differentiation of intestinal epithelioid IEC-6 into insulin-producing cells.

Authors:  Shigeru Yoshida; Yoshitaka Kajimoto; Tetsuyuki Yasuda; Hirotaka Watada; Yoshio Fujitani; Hiroshi Kosaka; Takahiro Gotow; Takeshi Miyatsuka; Yutaka Umayahara; Yoshimitsu Yamasaki; Masatsugu Hori
Journal:  Diabetes       Date:  2002-08       Impact factor: 9.461

Review 3.  Pancreatic stem cells.

Authors:  Susan Bonner-Weir; Arun Sharma
Journal:  J Pathol       Date:  2002-07       Impact factor: 7.996

Review 4.  GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells.

Authors:  Josephine M Egan; Angela Bulotta; Hongxiang Hui; Riccardo Perfetti
Journal:  Diabetes Metab Res Rev       Date:  2003 Mar-Apr       Impact factor: 4.876

Review 5.  Type 1 diabetes: new perspectives on disease pathogenesis and treatment.

Authors:  M A Atkinson; G S Eisenbarth
Journal:  Lancet       Date:  2001-07-21       Impact factor: 79.321

6.  Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas.

Authors:  D A Stoffers; T J Kieffer; M A Hussain; D J Drucker; S Bonner-Weir; J F Habener; J M Egan
Journal:  Diabetes       Date:  2000-05       Impact factor: 9.461

7.  Pancreas donation for islet transplantation.

Authors:  M A Frutos; P Ruiz; J J Mansilla
Journal:  Transplant Proc       Date:  2005-04       Impact factor: 1.066

8.  neurogenin3 is required for the development of the four endocrine cell lineages of the pancreas.

Authors:  G Gradwohl; A Dierich; M LeMeur; F Guillemot
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

9.  Combined expression of pancreatic duodenal homeobox 1 and islet factor 1 induces immature enterocytes to produce insulin.

Authors:  Hideto Kojima; Takaaki Nakamura; Yukihiro Fujita; Akio Kishi; Mineko Fujimiya; Syu Yamada; Motoi Kudo; Yoshihiko Nishio; Hiroshi Maegawa; Masakazu Haneda; Hitoshi Yasuda; Itaru Kojima; Masaharu Seno; Norman C W Wong; Ryuichi Kikkawa; Atsunori Kashiwagi
Journal:  Diabetes       Date:  2002-05       Impact factor: 9.461

10.  Glucagon-like peptide-1 gene therapy in obese diabetic mice results in long-term cure of diabetes by improving insulin sensitivity and reducing hepatic gluconeogenesis.

Authors:  Young-Sun Lee; Seungjin Shin; Toshikatsu Shigihara; Eunsil Hahm; Meng-Ju Liu; Jaeseok Han; Ji-Won Yoon; Hee-Sook Jun
Journal:  Diabetes       Date:  2007-03-16       Impact factor: 9.461

View more
  7 in total

1.  The time has come for incretins, a long time coming.

Authors:  Friedrich C Luft
Journal:  J Mol Med (Berl)       Date:  2010-01-26       Impact factor: 4.599

2.  High dosage of Exendin-4 increased early insulin secretion in differentiated beta cells from mouse embryonic stem cells.

Authors:  Hua Li; Amy Lam; Ai-min Xu; Karen Sl Lam; Sookja Kim Chung
Journal:  Acta Pharmacol Sin       Date:  2010-04-26       Impact factor: 6.150

3.  Cell replacement and regeneration therapy for diabetes.

Authors:  Hee-Sook Jun
Journal:  Korean Diabetes J       Date:  2010-04-30

Review 4.  Glucagon-like peptide-1 gene therapy.

Authors:  Anne M Rowzee; Niamh X Cawley; John A Chiorini; Giovanni Di Pasquale
Journal:  Exp Diabetes Res       Date:  2011-06-20

Review 5.  Transgene and islet cell delivery systems using nano-sized carriers for the treatment of diabetes mellitus.

Authors:  Kiyonori Ito; Susumu Ookawara; Kenichi Ishibashi; Yoshiyuki Morishita
Journal:  Nano Rev Exp       Date:  2017-06-25

Review 6.  Pancreatic β cell regeneration induced by clinical and preclinical agents.

Authors:  Kang-Li Wang; Ming Tao; Tian-Jiao Wei; Rui Wei
Journal:  World J Stem Cells       Date:  2021-01-26       Impact factor: 5.326

7.  Comparison of enteroendocrine cells and pancreatic β-cells using gene expression profiling and insulin gene methylation.

Authors:  Gyeong Ryul Ryu; Esder Lee; Jong Jin Kim; Sung-Dae Moon; Seung-Hyun Ko; Yu-Bae Ahn; Ki-Ho Song
Journal:  PLoS One       Date:  2018-10-31       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.